$39.13
1.66% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US4131971040
Symbol
HRMY

Harmony Biosciences Holdings Stock price

$39.13
+3.51 9.85% 1M
+5.61 16.74% 6M
+6.83 21.15% YTD
+5.38 15.94% 1Y
+0.97 2.54% 3Y
+2.12 5.73% 5Y
+2.12 5.73% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.66 1.66%
ISIN
US4131971040
Symbol
HRMY
Sector
Industry

Key metrics

Market capitalization $2.26b
Enterprise Value $2.13b
P/E (TTM) P/E ratio 20.37
EV/FCF (TTM) EV/FCF 10.03
EV/Sales (TTM) EV/Sales 3.25
P/S ratio (TTM) P/S ratio 3.45
P/B ratio (TTM) P/B ratio 4.20
Revenue growth (TTM) Revenue growth 31.52%
Revenue (TTM) Revenue $656.11m
EBIT (operating result TTM) EBIT $178.09m
Free Cash Flow (TTM) Free Cash Flow $212.78m
Cash position $346.91m
EPS (TTM) EPS $1.95
P/E forward 17.92
P/S forward 3.19
EV/Sales forward 3.01
Short interest 68.77%
Show more

Is Harmony Biosciences Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Harmony Biosciences Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Harmony Biosciences Holdings forecast:

6x Buy
75%
2x Sell
25%

Analyst Opinions

8 Analysts have issued a Harmony Biosciences Holdings forecast:

Buy
75%
Sell
25%

Financial data from Harmony Biosciences Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
656 656
32% 32%
100%
- Direct Costs 159 159
33% 33%
24%
497 497
31% 31%
76%
- Selling and Administrative Expenses 161 161
25% 25%
25%
- Research and Development Expense 134 134
69% 69%
20%
203 203
18% 18%
31%
- Depreciation and Amortization 24 24
1% 1%
4%
EBIT (Operating Income) EBIT 178 178
21% 21%
27%
Net Profit 115 115
43% 43%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Harmony Biosciences Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harmony Biosciences Holdings Stock News

Neutral
PRNewsWire
one day ago
PLYMOUTH MEETING, Pa. , Sept. 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at 8:30 a.m.
Neutral
Investors Business Daily
7 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
PRNewsWire
about one month ago
PLYMOUTH MEETING, Pa. , Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: Boston Fireside Chat: Thursday, September 5, 2024, at 9:30 a.m.
More Harmony Biosciences Holdings News

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jeffrey Dayno
Employees 246
Founded 2017
Website www.harmonybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today